血压昼夜节律状态、动态血压控制、心血管疾病与肾脏疾病进展:慢性肾脏病多中心队列研究
该前瞻性观察性队列研究纳入意大利3家肾脏病诊所的906例高血压合并慢性肾脏病患者,按动态血压是否达标和夜间血压是否下降分为4组。结果显示,动态血压高于目标值或无论动态血压水平如何只要夜间血压不下降,均与心血管疾病和肾脏疾病进展风险升高相关。
要点
- 动态血压高于目标值时,无论夜间血压是否下降,心血管事件和肾脏疾病进展风险均升高。
- 动态血压达标但夜间血压不下降者,心血管事件风险(HR 2.06)和肾脏疾病进展风险(HR 1.82)仍升高。
- 夜间血压不下降是慢性肾脏病患者不良事件的独立危险因素。
核心结论
- 收缩期动态血压高于目标值或夜间血压不下降(无论动态血压是否达标),均与慢性肾脏病患者心血管疾病和肾脏疾病进展风险升高相关。
研究设计与样本
- 前瞻性观察性队列研究,纳入906例在意大利3家肾脏病诊所就诊的高血压合并慢性肾脏病患者。
主要发现
- 平均年龄63.8岁,61%为男性,26.4%患糖尿病,估算肾小球滤过率为41.1 ± 20.8 mL/min/1.73 m²。
- 4组中夜间血压下降且动态血压达标者占18.6%,夜间血压不下降且动态血压达标者占20.5%,夜间血压下降且动态血压高于目标值者占11.8%,夜间血压不下降且动态血压高于目标值者占49.1%。
- 动态血压高于目标值者中,夜间血压不下降组心血管事件风险(HR 2.79 [95% CI 1.64-4.75])和夜间血压下降组(HR 2.05 [95% CI 1.10-3.84])均高于参照组。
- 动态血压高于目标值者中,夜间血压不下降组肾脏疾病进展风险(HR 2.40 [95% CI 1.58-3.65])和夜间血压下降组(HR 2.11 [95% CI 1.28-3.48])均高于参照组。
- 动态血压达标但夜间血压不下降者,心血管终点事件风险(HR 2.06 [95% CI 1.15-3.68])和肾脏疾病进展风险(HR 1.82 [95% CI 1.17-2.82])均升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏多样化队列(所有入选者均为白人)。
- 存在未控制的残余混杂。
- 未来研究需要检验治疗夜间血压不下降是否能改善临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Ambulatory blood pressure (BP) monitoring allows concurrent evaluation of BP control and nocturnal BP dipping status, both related to adverse outcomes. However, few studies have assessed the prognostic role of combining information on dipping status and achieved ambulatory BP in patients with chronic kidney disease (CKD). STUDY DESIGN: Prospective observational cohort study. SETTING & PARTICIPANTS: 906 patients with hypertension and CKD attending 1 of 3 Italian nephrology clinics. EXPOSURE: Four groups were defined by simultaneously classifying systolic ambulatory BP levels as being at goal (daytime SBP <135 and nighttime SBP <120 mm Hg) or above goal, and the presence or absence of nocturnal dipping (nighttime to daytime SBP ratio of <0.9 versus ≥0.9). OUTCOME: The composite of time to initiation of maintenance dialysis or estimated glomerular filtration rate (eGFR) decline ≥50%, and the composite of fatal and nonfatal cardiovascular events. ANALYTICAL APPROACH: Multivariable Cox proportional hazards models were used to estimate risks of kidney disease progression and cardiovascular disease in the 4 exposure groups where nocturnal dipping with systolic ambulatory BP at goal was the reference group. RESULTS: The mean patient age was 63.8 years, 61% were male, and 26.4% had diabetes; eGFR was 41.1 ± 20.8 mL/min/1.73 m2. The dipping prevalence in each of the 4 groups was as follows: nocturnal dipping with ambulatory BP at goal, 18.6%; no nocturnal dipping with ambulatory BP at goal, 20.5%; nocturnal dipping with ambulatory BP above goal, 11.8%; and no nocturnal dipping with ambulatory BP above goal, 49.1%. Among patients with ambulatory BP above goal, the risk of cardiovascular events was greater in the absence (HR, 2.79 [95% CI, 1.64-4.75]) and presence (HR, 2.05 [95% CI, 1.10-3.84]) of nocturnal dipping. The same held true for risk of kidney disease progression (HRs of 2.40 [95% CI, 1.58-3.65] and 2.11 [95% CI, 1.28-3.48] in the absence and presence of nocturnal dipping, respectively). Patients at the ambulatory BP goal but who did not experience nocturnal dipping had an increased risk of the cardiovascular end point (HR, 2.06 [95% CI, 1.15-3.68]) and the kidney disease progression outcome (HR, 1.82 [95% CI, 1.17-2.82]). LIMITATIONS: Lack of a diverse cohort (all those enrolled were White). Residual uncontrolled confounding. CONCLUSIONS: Systolic ambulatory BP above goal or the absence of nocturnal dipping, regardless of ambulatory BP, is associated with higher risks of cardiovascular disease and kidney disease progression among patients with CKD. PLAIN-LANGUAGE SUMMARY: Among patients with chronic kidney disease (CKD), ambulatory blood pressure (BP) monitoring improves the identification of individuals at high risk of clinical disease outcomes. Those with uncontrolled ambulatory BP are known to have a higher risk of developing cardiovascular disease and kidney disease progression, particularly when their ambulatory BP does not decline by at least 10% at night. Whether this is also true for patients with presence of optimal ambulatory BP levels but a BP pattern of no nighttime decline is largely unknown. We measured ambulatory BP in 900 Italian patients with CKD and followed them for several years. We found that, independent of ambulatory BP level, the absence of nighttime reductions in BP was associated with worsening of CKD and more frequent cardiovascular events. The absence of nighttime declines in BP is an independent risk factor for adverse events among patients with CKD. Future studies are needed to examine whether treating the absence of nighttime declines in BP improves clinical outcomes.
引用
- Borrelli S, Garofalo C, Gabbai FB, et al. Dipping Status, Ambulatory Blood Pressure Control, Cardiovascular Disease, and Kidney Disease Progression: A Multicenter Cohort Study of CKD. Am J Kidney Dis. 2022. PMID: 35709922. doi:10.1053/j.ajkd.2022.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。